Aurinia Pharmaceuticals's top three insider shareholders as of September 29, 2026 are Kevin Tang (Chief Executive Officer, 13.04Mn shares), Peter Greenleaf (Chief Executive Officer, 1.84Mn shares), Matthew Maxwell Donley (Chief Operating Officer, 680.30K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kevin Tang | Chief Executive Officer | 0 | 13,044,106 | 13,044,106 | 69.2% | 02 Jun, 2026 |
| 2 | Peter Greenleaf | Chief Executive Officer | 1,840,379 | 0 | 1,840,379 | 9.8% | 03 Mar, 2026 |
| 3 | Matthew Maxwell Donley | Chief Operating Officer | 680,299 | 0 | 680,299 | 3.6% | 03 Mar, 2026 |
| 4 | Stephen P. Robertson | Chief Legal Officer | 588,848 | 0 | 588,848 | 3.1% | 11 Sep, 2026 |
| 5 | Joseph M Miller | Chief Financial Officer | 576,421 | 0 | 576,421 | 3.1% | 03 Mar, 2026 |
| 6 | Scott Michael Habig | Chief Commercial Officer | 456,338 | 0 | 456,338 | 2.4% | 07 Aug, 2024 |
| 7 | Volker Knappertz | Evp, Research And Development | 319,128 | 0 | 319,128 | 1.7% | 29 Feb, 2024 |
| 8 | Michael Robert Martin | Chief Business Officer | 315,023 | 0 | 315,023 | 1.7% | 06 Mar, 2023 |
| 9 | Neil Solomons | Chief Medical Officer | 178,252 | 0 | 178,252 | 0.9% | 04 Mar, 2022 |
| 10 | Greg Keenan | Svp, Chief Medical Officer | 154,449 | 0 | 154,449 | 0.8% | 10 Mar, 2026 |
| 11 | Ryan Cole | Chief Operating Officer | 116,144 | 0 | 116,144 | 0.6% | 20 May, 2026 |
| 12 | Michael S Hearne | Chief Financial Officer | 116,144 | 0 | 116,144 | 0.6% | 20 May, 2026 |
| 13 | David R.W. Jayne | Director | 100,863 | 0 | 100,863 | 0.5% | 25 Nov, 2024 |
| 14 | George M Jr Milne | Director | 78,733 | 0 | 78,733 | 0.4% | 23 May, 2023 |
| 15 | Robert Bindert Huizinga | Evp Of Research | 69,379 | 0 | 69,379 | 0.4% | 04 Mar, 2022 |
| 16 | Jill Leversage | Director | 37,971 | 0 | 37,971 | 0.2% | 25 Nov, 2024 |
| 17 | Karen L. Smith | Director | 37,479 | 0 | 37,479 | 0.2% | 25 Nov, 2024 |
| 18 | Jeffrey Allen Bailey | Director | 36,131 | 0 | 36,131 | 0.2% | 24 Nov, 2025 |
| 19 | Daniel Billen | Director | 28,141 | 0 | 28,141 | 0.1% | 22 May, 2024 |
| 20 | R. Hector Mackay-Dunn | Director | 18,595 | 0 | 18,595 | 0.1% | 22 May, 2024 |
| 21 | Brinda Balakrishnan | Director | 17,523 | 0 | 17,523 | 0.1% | 22 May, 2024 |
| 22 | Craig A Johnson | Director | 14,592 | 0 | 14,592 | 0.1% | 24 Nov, 2025 |
| 23 | Massimilano Colao | Chief Commercial Officer | 13,495 | 0 | 13,495 | 0.1% | 04 Mar, 2022 |
| 24 | Joseph P Hagan | Director | 11,961 | 0 | 11,961 | 0.1% | 23 May, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 10 Sep, 2026 | Stephen P. Robertson | Chief Legal Officer | Disposed S | 11,939 | $15.95 | $190.43K | 588,848 | Direct |
| 21 Aug, 2026 | Stephen P. Robertson | Chief Legal Officer | Disposed S | 20,975 | $16.97 | $355.95K | 600,787 | Direct |
| 04 Jun, 2026 | Jeffrey Allen Bailey | Director | Acquired A | 23,931 | $0.00 | $0 | 23,931 | Direct |
| 04 Jun, 2026 | Tina Susan Nova | Director | Acquired A | 23,931 | $0.00 | $0 | 23,931 | Direct |
| 04 Jun, 2026 | Craig A Johnson | Director | Acquired A | 23,931 | $0.00 | $0 | 23,931 | Direct |
| 04 Jun, 2026 | Kathleen Goetz | Director | Acquired A | 23,931 | $0.00 | $0 | 23,931 | Direct |
| 29 May, 2026 | Kevin Tang | Chief Executive Officer | Acquired P | 2,299 | $15.35 | $35.29K | 12,231,799 | Indirect |
| 29 May, 2026 | Kevin Tang | Chief Executive Officer | Acquired P | 262,682 | $15.31 | $4.02Mn | 12,494,481 | Indirect |
| 01 Jun, 2026 | Kevin Tang | Chief Executive Officer | Acquired P | 343,521 | $15.28 | $5.25Mn | 12,838,002 | Indirect |
| 01 Jun, 2026 | Kevin Tang | Chief Executive Officer | Acquired P | 99 | $15.34 | $1.52K | 12,838,101 | Indirect |
| 02 Jun, 2026 | Kevin Tang | Chief Executive Officer | Acquired P | 206,005 | $15.28 | $3.15Mn | 13,044,106 | Indirect |
| 02 Jun, 2026 | Kevin Tang | Chief Executive Officer | Acquired J | 10,000 | $1.65 | $16.50K | 10,000 | Indirect |
| 18 May, 2026 | Stephen P. Robertson | Chief Legal Officer | Acquired A | 115,541 | $0.00 | $0 | 621,402 | Direct |
| 18 May, 2026 | Michael S Hearne | Chief Financial Officer | Acquired A | 116,144 | $0.00 | $0 | 116,144 | Direct |
| 18 May, 2026 | Ryan Cole | Chief Operating Officer | Acquired A | 116,144 | $0.00 | $0 | 116,144 | Direct |
| 18 May, 2026 | Ryan Cole | Chief Operating Officer | Acquired A | 70,230 | $0.00 | $0 | 70,230 | Direct |
| 18 May, 2026 | Michael S Hearne | Chief Financial Officer | Acquired A | 70,230 | $0.00 | $0 | 70,230 | Direct |
| 06 Mar, 2026 | Greg Keenan | Svp, Chief Medical Officer | Disposed F | 8,069 | $14.32 | $115.55K | 154,449 | Direct |
| 27 Feb, 2026 | Kevin Tang | Director | Acquired P | 300,000 | $13.90 | $4.17Mn | 11,629,500 | Indirect |
| 27 Feb, 2026 | Peter Greenleaf | Chief Executive Officer | Acquired A | 196,403 | $0.00 | $0 | 1,941,269 | Direct |